{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T22:18:07Z","timestamp":1767046687634,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Severe cytokine release syndrome (sCRS) has emerged as an adverse complication in the early period of chimeric antigen receptor T cell (CART) therapy, while whether sCRS occurs in the late period remains unknown. Here, we reported two patients with late sCRS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>Case 1 was a 34-year-old female with refractory Philadelphia chromosome-positive B cell acute lymphoblastic leukemia. She achieved complete remission (CR) but experienced grade III CRS and hemophagocytic lymphohistiocytosis (HLH) 41 days after CD19-targeted CART (CART19) cells and CD22-targeted CART (CART22) cells infusion. Ineffective to tocilizumab and HLH-94 protocol (dexamethasone and etoposide), she died of a cerebral hemorrhage on day 55 after CART therapy. Case 2 was a 38-year-old male with IgG kappa multiple myeloma. He received autologous BCMA-targeted CART (BCMA-CART) therapy 4 months after HLA\u2013matched sibling (sister) donor transplantation and developed grade III CRS 163 days after CART administration, characterized by fever, hypotension, and skin lesions. Effective to methylprednisolone and tocilizumab, his clinical response persisted for over 6.0 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Severe CRS could occur in the late period after CART therapy as re-expansion of CART cells possessed the potential risk for late sCRS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.893928","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T11:48:52Z","timestamp":1654084132000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome"],"prefix":"10.3389","volume":"12","author":[{"given":"Jinping","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongsheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruochong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000471","article-title":"Performance of Anti-CD19 Chimeric Antigen Receptor T Cells in Genetically Defined Classes of Chronic Lymphocytic Leukemia","volume":"8","author":"Mancikova","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000845","article-title":"41BB-Based and CD28-Based CD123-Redirected T-Cells Ablate Human Normal Hematopoiesis In Vivo","volume":"8","author":"Baroni","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.552429","article-title":"Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1-2 Trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1806009","article-title":"Potential Lung Attack and Lethality Generated by EpCAM-Specific CAR-T Cells in Immunocompetent Mouse Models","volume":"9","author":"Qin","year":"2020","journal-title":"Oncoimmunology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000151","article-title":"Tisagenlecleucel in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma Patients Without Measurable Disease at Infusion","volume":"3","author":"Bishop","year":"2019","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and Safety of CAR19\/22 T-Cell Cocktail Therapy in Patients With Refractory\/Relapsed B-Cell Malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated With Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of Cytokine Release Syndrome Associated With the CAR T Cell Therapy Tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-018-0627-z","article-title":"Correction to: Grading of Cytokine Release Syndrome Associated With the CAR T Cell Therapy Tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and Therapeutic Guidelines for Hemophagocytic Lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-911x(199705)28:5<342::aid-mpo3>3.0.co;2-h","article-title":"HLH-94: A Treatment Protocol for Hemophagocytic Lymphohistiocytosis. HLH Study Group of the Histiocyte Society","volume":"28","author":"Henter","year":"1997","journal-title":"Med Pediatr Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-018-0672-7","article-title":"Anti-BCMA CAR-T Cells for Treatment of Plasma Cell Dyscrasia: Case Report on POEMS Syndrome and Multiple Myeloma","volume":"11","author":"Xu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late Events After Treatment With CD19-Targeted Chimeric Antigen Receptor Modified T Cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the Toxicities of CAR T-Cell Therapy","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic Lymphohistiocytosis-Like Toxicity (carHLH) After CD19-Specific CAR T-Cell Therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-Like Manifestations as a CRS Variant in Patients Receiving CD22 CAR T Cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1025","article-title":"Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies","volume":"69","author":"Fishman","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T Cells Expressing CD19 Chimeric Antigen Receptors for Acute Lymphoblastic Leukaemia in Children and Young Adults: A Phase 1 Dose-Escalation Trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.06.062","article-title":"Evaluating the Skin in Patients Undergoing Chimeric Antigen Receptor Modified T-Cell Therapy","volume":"75","author":"Rubin","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0636","article-title":"Bullous and Exanthematous Lesions Associated With Chimeric Antigen Receptor T-Cell Therapy in a Patient With Diffuse Large B-Cell Lymphoma","volume":"156","author":"Hu","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.12.016","article-title":"Cytokine Profile of Engraftment Syndrome in Pediatric Hematopoietic Stem Cell Transplant Recipients","volume":"22","author":"Khandelwal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine Release Syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of Predictive Biomarkers for Cytokine Release Syndrome After Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular Kinetics of CTL019 in Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"BLOOD"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T Cell Expansion and Prolonged Persistence in Pediatric Patients With ALL Treated With a Low-Affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B Cell Maturation Antigen-Specific CAR T Cells are Clinically Active in Multiple Myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity Against Hepatocellular Carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008221","article-title":"CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia Without HSC Toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"BLOOD"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely Related T-Memory Stem Cells Correlate With In Vivo Expansion of CAR.CD19-T Cells and are Preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01085-1","article-title":"IL-6 Trans-Signaling Promotes the Expansion and Anti-Tumor Activity of CAR T Cells","volume":"35","author":"Jiang","year":"2021","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.734593","article-title":"IL-7 and CCR2b Co-Expression-Mediated Enhanced CAR-T Survival and Infiltration in Solid Tumors","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.893928\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T11:48:55Z","timestamp":1654084135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.893928\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":37,"alternative-id":["10.3389\/fonc.2022.893928"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.893928","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"article-number":"893928"}}